Antonio M Risitano

Paroxysmal nocturnal hemoglobinuria and other complement-mediated hematological disorders.

A. Risitano, Antonio M Risitano, 2012, Immunobiology.

Selective strong synergism of Ruxolitinib and second generation tyrosine kinase inhibitors to overcome bone marrow stroma related drug resistance in chronic myelogenous leukemia.

Giovanni Martinelli, Nicola Esposito, Giuseppe Saglio, 2014, Leukemia research.

Complement C3dg-mediated erythrophagocytosis: implications for paroxysmal nocturnal hemoglobinuria.

Patrizia Ricci, Daniel Ricklin, John D Lambris, 2015, Blood.